A Study of Pevonedistat in Adult East Asian Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 16, 2016

Primary Completion Date

January 25, 2022

Study Completion Date

January 25, 2022

Conditions
Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
Interventions
DRUG

Pevonedistat 25 mg/m^2

Pevonedistat 25 mg/m\^2 intravenous infusion.

DRUG

Pevonedistat 44 mg/m^2

Pevonedistat 44 mg/m\^2 intravenous infusion.

DRUG

Pevonedistat 10 mg/m^2

Pevonedistat 10 mg/m\^2 intravenous infusion.

DRUG

Pevonedistat 20 mg/m^2

Pevonedistat 20 mg/m\^2 intravenous infusion.

DRUG

Azacitidine 75 mg/m^2

Azacitidine 75 mg/m\^2 intravenous or subcutaneous formulation.

Trial Locations (9)

112

Taipei Veterans General Hospital, Taipei

10048

National Taiwan University Hospital, Taipei

137701

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

Unknown

Maebashi

Nagoya

Sendai

Tokyo

519-763

Chonnam National University Hwasun Hospital, Jeonnam

120-752

Severance Hospital Yonsei University Health System - PPDS, Seoul

All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY